Grace Therapeutics (GRCE) CMO Macdonald R. Loch Receives 54,690-Share Award

What Happened
Macdonald R. Loch, Chief Medical Officer of Grace Therapeutics (GRCE), was granted a derivative award for 54,690 shares on August 28, 2026. The Form 4 lists the acquisition price as $0.00 (no cash paid at grant) and classifies the transaction as an award/acquisition (derivative). The filing’s footnote indicates these are options that vest over three years.

Key Details

• Transaction date: 2026-08-28; Form 4 filed 2026-09-01.
• Amount: 54,690 shares (derivative award) at $0.00 per share (no cash outlay shown).
• Vesting (footnote F1): Options vest quarterly over 3 years; first 1/12 vests immediately, remaining 11/12 vest equally over the next 11 quarters starting three months after grant.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form shows filing on Sep 1 for an Aug 28 grant; no late-filing flag provided in the data here.

Context
This was a compensation award (derivative/options) rather than an open-market buy or sale. Such grants are commonly used to align executive incentives with company performance; they do not necessarily indicate an immediate trading view by the insider. The award does not appear to involve an immediate sale or cashless exercise.